



CNIO Frontiers Meetings
Molecular Cancer Therapeutics
Madrid, March 8-10, 2010

Organisers

S. Gail Eckhardt, University of Colorado Denver, Aurora, USA
Roy S. Herbst, The University of Texas MD Anderson Cancer Center, Houston, USA
Manuel Hidalgo, CNIO, Madrid, Spain

MONDAY, MARCH 8th

9:00-9:15 **Welcome address**

Manuel Hidalgo, CNIO, Madrid, Spain

Session I: Emerging new cancer targets and drugs

Chair: Roy S. Herbst

- 9:15-9:50 **Douglas Yee**, University of Minnesota, Minneapolis, USA
"Targeting the insulin-like growth factor receptor as a new cancer therapy"
- 9:50-10:25 **Alex Adjei**, Roswell Park Cancer Institute, Buffalo, USA
"Targeting the Ras-Raf-MEK for cancer treatment"
- 10:25-11:00 **Patricia LoRusso**, The Barbara Ann Karmanos Cancer Institute, Detroit, USA
"Therapeutics targeting the c-Met pathway"
- 11:00-11:40 *Coffee break and poster session*
- 11:40-12:15 **Josep Tabernero**, Vall d'Hebron University Hospital, Barcelona, Spain
"Inhibitors of the PI3K-Akt pathway"
- 12:15-12:50 **Adrian Senderowicz**, AstraZeneca, Philadelphia, USA
"Development of JAK inhibitors for the treatment of human neoplasms"
- 12:50-14:20 *Lunch and poster session*

Session II: Lessons learned from recent successfully developed new agents

Chair: Alex Adjei

14:20-14:55 **Jaap Verweij**, Erasmus University Medical Center, Rotterdam, The Netherlands
“Clinical development of imatinib mesylate in GIST: Understanding the target”

14:55-15:30 **Gary Clark**, Array Biopharma, Boulder, USA
“Erlotinib: Strategies for a successful clinical development”

15:30-16:05 **Eric Rowinsky**, New York University School of Medicine, New York, USA
“Predictive biomarkers and the development and the EGFR-targeting monoclonal antibody cetuximab in colorectal cancer”

16:05-16:40 **Manuel Hidalgo**, CNIO, Madrid, Spain
“Pathway to approval for mTOR inhibitors: Luck or rationale?”

16:40-17:10 *Coffee break and poster session*

17:10-18:00 **Key note address**
Chair: S. Gail Eckhardt

Neal Rosen, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA
“Targeting oncogene addition”

Session III: Innovation in clinical trials design

Chair: Josep Tabernero

- 8:50-9:25 **Elizabeth Garrett**, Medical University of South Carolina, Charleston, USA
“Novel trial designs for early phase drug development”
- 9:25-10:00 **Lillian Siu**, Ontario Cancer Institute, Toronto, Canada
“Using phase II trials to fulfill their “Go-No-Go” role”
- 10:00-10:35 **Emiliano Calvo**, Centro Oncológico Clara Campal, Madrid, Spain
“Strategies to combine molecular targeted agents in the clinic”
- 10:35-11:10 **Lajos Pusztai**, University of Texas MD Anderson Cancer Center, Houston, USA
“Clinical trial design to prospectively test molecular markers and patient selection strategies”
- 11:10-11:40 *Group picture, coffee break and poster session*

Sesion IV: Emerging new anticancer agents


Chair: Lillian Siu

- 11:40-12:15 **Charles Rudin**, The Johns Hopkins University, Baltimore, USA
“Targeting the Hedgehog Pathway in Cancer”
- 12:15-12:50 **Johann de Bono**, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
“Biomarker driven early anticancer drug development”
- 12:50-13:25 **S. Gail Eckhardt**, University of Colorado Denver, Aurora, USA
“PAK-4, a novel cancer target”
- 13:25-15:00 *Lunch and poster session*

Session V: Short talks from selected posters

Chair: Elizabeth Garrett

- 15:00-15:20 Short talk # 1
- 15:20-15:40 Short talk # 2
- 15:40-16:00 Short talk # 3
- 16:00-16:20 Short talk # 2
- 16:20-16:40 Short talk # 3
- 16:40-17:10 *Coffee break and poster session*



17:10-18:00 **Key note address**
Chair: Manuel Hidalgo

Dan Von Hoff, Translational Genomics Research Institute, Phoenix, USA
“Personalising cancer drug development”

Session VI: Applying biomarkers to clinical cancer research

Chair: Emiliano Calvo

- 9:10-9:45 **Roy S. Herbst**, The University of Texas MD Anderson Cancer Center, Houston, USA
“Strategies to implement predictive biomarkers in clinical trials”
- 09:45-10:20 **Antonio Jimeno**, The University of Colorado Denver, Aurora, USA
“Pharmacodynamic studies in anticancer drug development”
- 10:20-10:55 **Richard Wahl**, The Johns Hopkins PET Center, Baltimore, USA
“Functional imaging in drug development”

10:55 Closing remarks and poster prize

Roy S. Herbst, The University of Texas MD Anderson Cancer Center, Houston, USA
S. Gail Eckhardt, University of Colorado Denver, Aurora, USA

Note: Talks: 25 minutes / Short talk: 15 minutes / Key note: 40 minutes

Discussion: 10 minutes after each talk / 5 minutes after each short talk / 10 minutes after each key note